This category page covers biotechnology and pharmaceutical companies developing therapies for behavioral and psychological symptoms of dementia (BPSD) in Alzheimer's disease. BPSD encompasses a range of neuropsychiatric symptoms including agitation, aggression, depression, apathy, anxiety, hallucinations, and delusions. These symptoms significantly impact patient quality of life and caregiver burden.
The global BPSD treatment market is experiencing significant growth, driven by:
| Mechanism | Target Symptoms | Companies |
|---|---|---|
| 5-HT2A inverse agonists | Psychosis, agitation | Acadia, Otsuka |
| Sigma-1 receptor agonists | Agitation, anxiety | Axsome |
| GLP-1 receptor agonists | Cognitive decline, apathy | Novo Nordisk |
| Dopamine modulators | Motivation, apathy | Neurocrine |
| Anti-amyloid with BPSD benefits | Overall BPSD | Biogen/Eisai |
Axsome Therapeutics is developing AXS-060, a sigma-1 receptor agonist for Alzheimer's disease agitation. Sigma-1 receptor activation has demonstrated neuroprotective effects and modulation of neuroinflammation.
Otsuka Pharmaceutical is a Japanese pharmaceutical leader with significant CNS expertise, developing brexpiprazole (Rexulti) for Alzheimer's disease psychosis and agitation. Brexpiprazole has a unique pharmacology as a serotonin-dopamine activity modulator.
Biogen focuses on disease-modifying therapies for Alzheimer's disease (Leqembi, Aduhelm). By reducing amyloid burden, these therapies may subsequently reduce BPSD symptoms associated with amyloid pathology.
Acadia Pharmaceuticals is a leader in neuropsychiatric drug development with Nuplazid (pimavanserin) approved for Parkinson's disease psychosis. The company is developing pimavanserin for Alzheimer's disease psychosis.
Biohaven, acquired by Pfizer in 2023, is developing Kv7 potassium channel modulators and TDP-43 targeting therapies for neurodegeneration. Their platform addresses neuronal hyperexcitability implicated in neuropsychiatric symptoms.
Novo Nordisk is a major pharmaceutical company with a dominant position in metabolic diseases. Their GLP-1 receptor agonists (Ozempic, Wegovy) are being investigated for neuroprotective effects in Alzheimer's and Parkinson's disease.
Neurocrine Biosciences focuses on neuropsychiatric and neurological disorders. Their expertise in dopamine and GPCR signaling positions them for BPSD therapies targeting apathy and motivational symptoms.
| Company | Market Cap (2026) | Key BPSD Program | Stage |
|---|---|---|---|
| Acadia | ~$6B | Pimavanserin (AD psychosis) | Phase 3 |
| Axsome | ~$6B | AXS-060 (agitation) | Phase 2/3 |
| Otsuka | ~$20B | Brexpiprazole (AD psychosis) | Phase 3 |
| Biogen | ~$20B | Leqembi (BPSD benefit) | Approved |
| Novo Nordisk | ~$500B | Semaglutide (AD) | Phase 3 |
| Biohaven (Pfizer) | — | Kv7 modulators | Preclinical |
| Company | Drug | NCT Number | Indication | Phase |
|---|---|---|---|---|
| Acadia | Pimavanserin | NCT04331301 | AD Psychosis | Phase 3 |
| Axsome | AXS-060 | NCT05431461 | AD Agitation | Phase 2/3 |
| Otsuka | Brexpiprazole | NCT03902240 | AD Agitation | Phase 3 |
| Novo Nordisk | Semaglutide | NCT04777409 | AD (EVOKE) | Phase 3 |
| Novo Nordisk | Semaglutide | NCT04777396 | AD (EVOKE+) | Phase 3 |